Regulatory Affairs Outsourcing Market Introduction and Overview
According to SPER Market Research, the Global Regulatory Affairs Outsourcing Market is estimated to reach USD 20896.18 million by 2033 with a CAGR of 10.92%.
The report includes an in-depth analysis of the Global Regulatory Affairs Outsourcing Market, including market size and trends, product mix, Applications, and supplier analysis. The services used by biotech, pharmaceutical, and medical device manufacturers to quickly obtain regulatory approvals from several agencies are known as regulatory affairs outsourcing. Regulatory mostly entails rigorous testing of a specific product to guarantee protection of public health, marketing authorization, import and distribution, and compliance with product safety and performance requirements. The process of assigning regulatory affairs responsibilities, compliance oversight, and communication with regulatory bodies to outside service providers is known as healthcare regulatory affairs outsourcing. Pharmaceutical, biotechnology, and medical device companies may contract with specialized companies to handle these vital tasks, which include navigating complex regulatory environments, making sure standards are followed, and assisting with the approval and marketing of healthcare products that comply with legal requirements.
- AmerisourceBergen Corporation purchased PharmaLex Holding GmbH in January 2023. PharmaLex Holding GmbH is a well-known service provider in the life sciences sector that handles regulatory affairs. The company's service offering has expanded in a sizable market as a result.
- EC Innovations, a Chinese translation services provider with extensive experience translating highly regulated life sciences and medical content, and VCLS partnered in April 2022. The company's offers and operational capabilities were strengthened by the approach.
Market Opportunities and Challenges
The primary driver of the regulatory affairs outsourcing market is a notable increase in the fixed expenses of in-house resources for regulatory affairs and operating operations, such as facilities, technology, specialist knowledge, and training. Another factor propelling the market for regulatory affairs outsourcing is the increase in clinical trials. The market for regulatory affairs outsourcing has an opportunity due to the process improvement that focuses on pre- and post-marketing activities and the decrease in regulatory service costs. The aging population, rising healthcare costs, and the creation of novel treatments and medical equipment are all contributing to the fast expansion of the pharmaceutical and healthcare industries worldwide. As a result of this expansion, there is a significant opportunity for regulatory affairs outsourcing as businesses look for effective solutions to manage complicated regulatory environments and launch products more quickly.
Sensitive and private information, such as data from clinical trials and proprietary products, is frequently involved in regulatory concerns. Because they are worried about data security, confidentiality breaches, and intellectual property protection, companies could be reluctant to outsource these tasks. It can also be difficult to maintain uniform quality standards and monitoring when regulatory affairs are outsourced. Concerns over the degree of control over regulatory procedures that companies have and the ability of external providers to uphold the same standards of quality and compliance may arise. New rules and norms are continually being implemented in many areas and industries, resulting in constantly changing regulatory frameworks. It can be quite difficult for outsourcing companies and their clients to stay on top of these developments and guarantee compliance in several jurisdictions.
Market Competitive Landscape
There are a number of significant businesses in the competitive and fragmented regulatory affairs outsourcing market. Accell Clinical Research, LLC, Genpact, CRITERIUM, INC, Promedica International, WuXi AppTec, Medpace, Charles River Laboratories, ICON plc, Labcorp Drug Development, Parexel International Corporation, Freyr, PHARMALEX GMBH, NDA Group AB, Pharmexon, Qvigilance, BlueReg, Cambridge Regulatory Services, APCER Life Sciences, Inc., Real Regulatory Ltd., PrimeVigilance, and ProPharma Group MIS Limited are a few of the top companies in the sector.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Service, By Category, By Indication, By Product Stage, By End User
|
| Regions covered | North America, Asia-Pacific, Latin America, Middle East & Africa and Europe
|
| Companies Covered | Accell Clinical Research, LLC, Genpact, CRITERIUM, INC, Promedica International, WuXi AppTec, Medpace, Charles River Laboratories, ICON plc, Labcorp Drug Development, Parexel International Corporation, Freyr, PHARMALEX GMBH, NDA Group AB, Pharmexon, Qvigilance, BlueReg, Cambridge Regulatory Services, APCER Life Sciences, Inc, Real Regulatory Ltd, VCLS, PrimeVigilance, ProPharma Group MIS Limited.
|
COVID-19 Impact on Global Regulatory Affairs Outsourcing Market
Mass lockdowns brought forth by the pandemic's large intake of COVID-19 patients interrupted clinical trials for a number of chronic illnesses, including cancer. The demand for healthcare regulatory affairs outsourcing services declined as a result of the pandemic's fall in the number of clinical studies. As a result, during the early stages of the pandemic, manufacture and distribution of pharmaceutical products were impacted by disruptions in the worldwide supply chain, which had a substantial effect on market growth. Regulatory affairs teams had to overcome obstacles in order to guarantee the security and accessibility of necessary medications, which required adjusting regulations.
Key Target Audience:
- Pharmaceutical Companies
- Biotechnology Firms
- Medical Device Manufacturers
- Healthcare Institutions
- Contract Research Organizations
- Regulatory Authorities
- Legal Firms
- Investors and Stakeholders
Our in-depth analysis of the Regulatory Affairs Outsourcing Market includes the following segments:
|
By Service:
|
Regulatory Consulting
Legal Representation
Regulatory Writing & Publishing
Product Registration & Clinical Trial Applications
Regulatory Operations
Regulatory Submission
Others
|
|
By Category:
|
Pharmaceuticals
Medical Device
Others
|
|
By Indication:
|
Oncology
Neurology
Cardiology
Immunology
Others
|
|
By Product Stage:
|
Clinical
PMA (Post Market Authorization
|
|
By End User:
|
Medical Device Companies
Pharmaceutical Companies
Biotechnology Companies
Others
|
Key Topics Covered in the Report
- Global Regulatory Affairs Outsourcing Market Size (FY’2024-FY’2033)
- Overview of Global Regulatory Affairs Outsourcing Market
- Segmentation of Global Regulatory Affairs Outsourcing Market By Service (Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical Trial Applications, Regulatory Operations, Regulatory Submissions, Others)
- Segmentation of Global Regulatory Affairs Outsourcing Market By Category (Pharmaceuticals, Medical Device, Others)
- Segmentation of Global Regulatory Affairs Outsourcing Market By Indication (Oncology, Neurology, Cardiology, Immunology, Others)
- Segmentation of Global Regulatory Affairs Outsourcing Market By Product Stage (Preclinical, Clinical, PMA, Others)
- Segmentation of Global Regulatory Affairs Outsourcing Market By End User (Medical Device Companies, Pharmaceutical Companies, Biotechnology Companies, Others)
- Statistical Snap of Global Regulatory Affairs Outsourcing Market
- Expansion Analysis of Global Regulatory Affairs Outsourcing Market
- Problems and Obstacles in Global Regulatory Affairs Outsourcing Market
- Competitive Landscape in the Global Regulatory Affairs Outsourcing Market
- Impact of COVID-19 and Demonetization on Global Regulatory Affairs Outsourcing Market
- Details on Current Investment in Global Regulatory Affairs Outsourcing Market
- Competitive Analysis of Global Regulatory Affairs Outsourcing Market
- Prominent Players in the Global Regulatory Affairs Outsourcing Market
- SWOT Analysis of Global Regulatory Affairs Outsourcing Market
- Global Regulatory Affairs Outsourcing Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Regulatory Affairs Outsourcing Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Regulatory Affairs Outsourcing Market Manufacturing Base Distribution, Sales Area, Ingredients
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Regulatory Affairs Outsourcing Market
7. Global Regulatory Affairs Outsourcing Market, By Service (USD Million)
7.1. Global Regulatory Affairs Outsourcing Market Value Share and Forecast, By Service 2024-2033
7.2. Regulatory Consulting
7.2.1. Strategy & Development Planning
7.2.2. QA Consulting
7.2.3. Others
7.3. Legal Representation
7.4. Regulatory Writing & Publishing
7.5. Product Registration & Clinical Trial Applications
7.6. Regulatory Operations
7.7. Regulatory Submission
7.8. Others
8. Global Regulatory Affairs Outsourcing Market, By Category (USD Million)
8.1. Global Regulatory Affairs Outsourcing Market Value Share and Forecast, By Category 2024-2033
8.2. Pharmaceuticals
8.2.1. Regulatory Consulting
8.2.2. Legal Representation
8.2.3. Regulatory Writing & Publishing
8.2.4. Product Registration & Clinical Trial Applications
8.2.5. Regulatory Submissions
8.2.6. Regulatory Operations
8.2.7. Others
8.3. Medical Device
8.3.1. Regulatory Consulting
8.3.2. Legal Representation
8.3.3. Regulatory Writing & Publishing
8.3.4. Product Registration & Clinical Trial Applications
8.3.5. Regulatory Submissions
8.3.6. Regulatory Operations
8.4. Others
9. Global Regulatory Affairs Outsourcing Market, By Indication (USD Million)
9.1. Global Regulatory Affairs Outsourcing Market Size Value Share and Forecast, By Indication 2024-2033
9.2. Oncology
9.3. Neurology
9.4. Cardiology
9.5. Immunology
9.6. Others
10. Global Regulatory Affairs Outsourcing Market, By Product Stage (USD Million)
10.1. Global Regulatory Affairs Outsourcing Market Size Value Share and Forecast, By Product Stage 2024-2033
10.2. Preclinical
10.3. Clinical
10.4. PMA (Post Market Authorization
11. Global Regulatory Affairs Outsourcing Market, By End User (USD Million)
11.1. Global Regulatory Affairs Outsourcing Market Size Value Share and Forecast, By End User 2024-2033
11.2. Medical Device Companies
11.3. Pharmaceutical Companies
11.4. Biotechnology Companies
11.5. Others
12. Global Regulatory Affairs Outsourcing Market, Forecast, 2020-2033 (USD Million)
12.1. Global Regulatory Affairs Outsourcing Market Size and Market Share
13. Global Regulatory Affairs Outsourcing Market, By Service 2020-2033 (USD Million)
13.1. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Service (2020-2026)
13.2. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Service (2027-2033)
14. Global Regulatory Affairs Outsourcing Market, By Category 2020-2033 (USD Million)
14.1. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Category (2020-2026)
14.2. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Category (2027-2033)
15. Global Regulatory Affairs Outsourcing Market, By Indication 2020-2033 (USD Million)
15.1. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Indication (2020-2026)
15.2. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Indication (2027-2033)
16. Global Regulatory Affairs Outsourcing Market, By Product Stage 2020-2033 (USD Million)
16.1. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Product Stage (2020-2026)
16.2. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Product Stage (2027-2033)
17. Global Regulatory Affairs Outsourcing Market, By End User 2020-2033 (USD Million)
17.1. Global Regulatory Affairs Outsourcing Market Size and Market Share, By End User (2020-2026)
17.2. Global Regulatory Affairs Outsourcing Market Size and Market Share, By End User (2027-2033)
18. Global Regulatory Affairs Outsourcing Market, By Region, 2020-2033 (USD Million)
18.1. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Region (2020-2026)
18.2. Global Regulatory Affairs Outsourcing Market Size and Market Share, By Region (2027-2033)
18.3. Asia-Pacific
18.3.1. Australia
18.3.2. China
18.3.3. India
18.3.4. Japan
18.3.5. South Korea
18.3.6. Rest of Asia-Pacific
18.4. Europe
18.4.1. France
18.4.2. Germany
18.4.3. Italy
18.4.4. Spain
18.4.5. United Kingdom
18.4.6. Rest of Europe
18.5. Middle East and Africa
18.5.1. Kingdom of Saudi Arabia
18.5.2. United Arab Emirates
18.5.3. Rest of Middle East & Africa
18.6. North America
18.6.1. Canada
18.6.2. Mexico
18.6.3. United States
18.7. Latin America
18.7.1. Argentina
18.7.2. Brazil
18.7.3. Rest of Latin America
19. Company Profile
19.1. Accell Clinical Research, LLC
19.1.1. Company details
19.1.2. Financial outlook
19.1.3. Product summary
19.1.4. Recent developments
19.2. Genpact
19.2.1. Company details
19.2.2. Financial outlook
19.2.3. Product summary
19.2.4. Recent developments
19.3. CRITERIUM, INC
19.3.1. Company details
19.3.2. Financial outlook
19.3.3. Product summary
19.3.4. Recent developments
19.4. Promedica International
19.4.1. Company details
19.4.2. Financial outlook
19.4.3. Product summary
19.4.4. Recent developments
19.5. WuXi AppTec
19.5.1. Company details
19.5.2. Financial outlook
19.5.3. Product summary
19.5.4. Recent developments
19.6. Medpace
19.6.1. Company details
19.6.2. Financial outlook
19.6.3. Product summary
19.6.4. Recent developments
19.7. Charles River Laboratories
19.7.1. Company details
19.7.2. Financial outlook
19.7.3. Product summary
19.7.4. Recent developments
19.8. ICON plc
19.8.1. Company details
19.8.2. Financial outlook
19.8.3. Product summary
19.8.4. Recent developments
19.9. Labcorp Drug Development
19.9.1. Company details
19.9.2. Financial outlook
19.9.3. Product summary
19.9.4. Recent developments
19.10. Parexel International Corporation
19.10.1. Company details
19.10.2. Financial outlook
19.10.3. Product summary
19.10.4. Recent developments
19.11. Freyr
19.11.1. Company details
19.11.2. Financial outlook
19.11.3. Product summary
19.11.4. Recent developments
19.12. PHARMALEX GMBH
19.12.1. Company details
19.12.2. Financial outlook
19.12.3. Product summary
19.12.4. Recent developments
19.13. NDA Group AB
19.13.1. Company details
19.13.2. Financial outlook
19.13.3. Product summary
19.13.4. Recent developments
19.14. Pharmexon
19.14.1. Company details
19.14.2. Financial outlook
19.14.3. Product summary
19.14.4. Recent developments
19.15. Qvigilance
19.15.1. Company details
19.15.2. Financial outlook
19.15.3. Product summary
19.15.4. Recent developments
19.16. BlueReg
19.16.1. Company details
19.16.2. Financial outlook
19.16.3. Product summary
19.16.4. Recent developments
19.17. Cambridge Regulatory Services
19.17.1. Company details
19.17.2. Financial outlook
19.17.3. Product summary
19.17.4. Recent developments
19.18. APCER Life Sciences, Inc.
19.18.1. Company details
19.18.2. Financial outlook
19.18.3. Product summary
19.18.4. Recent developments
19.19. Real Regulatory Ltd
19.19.1. Company details
19.19.2. Financial outlook
19.19.3. Product summary
19.19.4. Recent developments
19.20. VCLS
19.20.1. Company details
19.20.2. Financial outlook
19.20.3. Product summary
19.20.4. Recent developments
19.21. PrimeVigilance
19.21.1. Company details
19.21.2. Financial outlook
19.21.3. Product summary
19.21.4. Recent developments
19.22. ProPharma Group MIS Limited
19.22.1. Company details
19.22.2. Financial outlook
19.22.3. Product summary
19.22.4. Recent developments
19.23. Others
20. List of Abbreviations
21. Reference Links
22. Conclusion
23. Research Scope